Study of the Effectiveness of Green Diode Laser Light on Body Shaping
Launched by ERCHONIA CORPORATION · Feb 8, 2011
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
Weight loss and body contouring are large, constantly-growing fields of cosmetic surgery. However, while the demand for body shaping procedures is constantly on the rise, so is the demand for such procedures to be performed more quickly, simply and most importantly, less invasively; hence the growing popularity of non- to minimally-invasive cosmetic surgery procedures. In 2005, more than 7.5 million minimally-invasive cosmetic procedures were performed, a 35% increase from 2000.
In recent years, Erchonia Corporation, a manufacturer of low level lasers, has developed a dual-diode laser that...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Body Mass Index (BMI) less than 30 kg/m²
- • Subject indicated for liposuction or use of liposuction techniques for the removal of localized deposits of adipose tissues that do not respond to diet and exercise; specifically for the indication of body contouring in the areas of the waist, hips and bilateral thighs. (As per the American Academy of Cosmetic Surgery's 2006 Guidelines for Liposuction Surgery).
- • Subject is willing and able to abstain from partaking in any treatment other than the study procedure to promote body contouring and/or weight loss during study participation.
- • Subject is willing and able to maintain his or her regular diet and exercise regimen without effecting significant change in either direction during study participation.
- Exclusion Criteria:
- • Body Mass Index (BMI) of 30 kg/m² or greater.
- • Diabetic dependent on insulin or oral hypoglycemic medications.
- • Known cardiovascular disease.
- • Prior cardiac surgery.
- • Prior surgical intervention for body sculpting/weight loss, such as liposuction, abdominoplasty, stomach stapling, lap band surgery.
- • Medical, physical, or other contraindications for body sculpting/weight loss.
- • Use of medication(s) known to affect weight levels and/or to cause bloating or swelling and for which abstinence during study participation is not safe or medically prudent.
- • Any medical condition known to affect weight levels and/or cause bloating or swelling.
- • Diagnosis of, and/or taking medication for, irritable bowel syndrome.
- • Active infection, wound or other external trauma to the areas to be treated with the laser.
- • Photosensitivity disorder.
- • Current cancer or receiving treatment for cancer.
- • Pregnant, breast feeding, or planning pregnancy prior to study end.
- • Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in past two years.
- • Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to record study measurements.
- • Involvement in litigation and/or a worker's compensation claim and/or receiving disability benefits related to weight-related/body shape issues.
- • Participation in research in the past 30 days.
About Erchonia Corporation
Erchonia Corporation is a leading innovator in the field of low-level laser therapy (LLLT), dedicated to advancing non-invasive treatment solutions for various medical conditions. With a focus on research and development, Erchonia is committed to delivering safe and effective therapeutic devices that enhance patient outcomes. The company collaborates with healthcare professionals and clinical researchers to validate the efficacy of its technologies through rigorous clinical trials, ensuring compliance with regulatory standards. By merging cutting-edge science with practical applications, Erchonia aims to redefine pain management and promote overall well-being in diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marion, Indiana, United States
Bloomfield Hills, Michigan, United States
Patients applied
Trial Officials
Gregory C Roche, MD, FACS
Principal Investigator
Robert F Jackson, MD, FACS
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials